Table 2: Mutational status of DNA from urine samples.
|
dPCR reaction |
BC n 21 (%) |
T+ n 8 (%) |
No BC n 9 (%) |
|
|
FGFR3 |
42 dPCRs |
|||
|
Wild-type |
16 (76) |
3 (38) |
8 (88) |
|
|
Mutated |
5 (24) |
5 (62) |
1 (12) |
|
|
Not determined |
0 |
0 |
0 |
|
|
TERT promoter |
51 dPCRs |
|||
|
Wild-type |
11 (65) |
1 (13) |
9 (100) |
|
|
Mutated |
6 (35) |
7 (87) |
0 |
|
|
Not determined |
4 |
0 |
0 |
|
|
STAG2 |
25 dPCRs |
|||
|
Wild-type |
1 (15) |
5 (63) |
8 (88) |
|
|
Mutated |
6 (85) |
3 (37) |
1 (12) |
|
|
Not determined |
14 |
0 |
0 |
|
|
FGFR3m and TERTm |
39 dPCRs |
4 (23) |
4 (50) |
0 |
|
FGFR3m and STAG2m |
23 dPCRs |
5 (71) |
7(87) |
0 |
|
STAG2wt and TERTm |
24 dPCRs |
5 (71) |
5 (62) |
0 |
|
All 3 mutated |
22 dPCRs |
2 (28) |
4 (50) |
0 |
|
No mutations |
22 dPCRs |
8 (72) |
0 |
9 (100) |
BC-patients with diagnosed BC; T+ -patients with tumor confirmed within 6 months of recent DNA analysis; no BC-control subjects.